EC approves Novo Holdings' buy of Catalent

The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings.

The Commission concluded that the transaction would not raise competition concerns in the European Economic Area (EEA).

Novo Holdings announced its $16.5 billion bid for Catalent back in February, and the deal for Novo Nordisk (NOV: N), which is majority controlled by Novo Holdings, to acquire three of Catalent’s manufacturing sites are specialized in the sterile filling of drugs and located in Anagni (Italy), Brussels (Belgium) and Bloomington (Indiana, USA), at a cost of $11 billion.